secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001816736-25-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine Q2 net loss $55.2M; on track for bitopertin NDA in October 2025
-----------------------------------------------------------------------------

- Cash of $650.0M as of June 30, 2025; expected to fund operations into 2028.
- NDA submission for bitopertin in EPP under accelerated approval planned for October 2025 after positive pre-NDA meeting.
- Phase 2 data from DISC-0974 in MF anemia and multiple-dose data from Phase 1b in NDD-CKD anemia expected Q4 2025.
- Initiated Phase 2 study of DISC-3405 in polycythemia vera; initial data anticipated in 2026.
- Appointed Nadim Ahmed (Cullinan Therapeutics CEO) to Board of Directors in July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/0001816736-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/iron-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001816736-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer